Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of clonazepam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of clonazepam can be broken down into several components which progressively intensify proportional to dosage. The general head space of clonazepam is described by many as one of intense relaxation, anxiety suppression and decreased inhibition. It contains a large number of typical depressant cognitive effects. Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Extremely high psychological addiction potential. Dependence develops in approximately one-third of individuals who take benzodiazepines for longer than four weeks. The U.S. FDA mandates boxed warnings describing risks of abuse, misuse, and addiction for all benzodiazepine medications.
Physical dependence develops readily with regular use, and discontinuation can be life-threatening. Withdrawal symptoms include anxiety, irritability, insomnia, tremors, sweating, confusion, and hallucinations. Severe withdrawal may cause seizures comparable to delirium tremens. Gradual tapering over weeks to months is essential for safe discontinuation.
Overdose with clonazepam alone is generally not life-threatening. Coma, if it occurs, typically lasts a few hours but may be more protracted and cyclical in elderly patients. Fatal respiratory depression can occur when combined with other CNS depressants such as alcohol, opioids, or barbiturates.
| Species | Route | Value |
|---|---|---|
| mouse | oral | 4000 mg/kg |
| rat | oral | 4000 mg/kg |
| rabbit | oral | 2000 mg/kg |
Psychosis is a rare adverse effect during use, with paradoxical reactions including hallucinations occurring in less than 1% of the general population. Risk is elevated in recreational abusers, individuals with mental disorders, children, and those on high-dosage regimens. Psychosis can also occur during severe withdrawal, characterized by dysphoric manifestations, aggressiveness, anxiety, and hallucinations.
Although clonazepam is an anticonvulsant, paradoxical increases in seizure frequency can occur at supratherapeutic plasma concentrations. Critically, abrupt discontinuation after regular use can induce potentially life-threatening seizures including status epilepticus. Gradual dose tapering is essential to prevent withdrawal-related seizures.
Clonazepam was patented in 1960 and first marketed in 1964 before being released for sale in the United States by Roche in 1975. The medication was subsequently approved as a generic drug in the United States in 1997 and is now manufactured and marketed by multiple pharmaceutical companies.…
United Nations Convention on Psychotropic Substances 1971 (Schedule IV)
Available exclusively through medical prescription. Unauthorized possession or supply constitutes an offense under state and territory drugs legislation.
Controlled under the Controlled Drugs and Substances Act. Requires a prescription for lawful possession. Manufacturing and distribution without authorization carries criminal penalties.
Listed in Schedule III of the Betäubungsmittelgesetz (Narcotics Act) since August 1, 1986. Requires a narcotic prescription form (Betäubungsmittelrezept) for dispensing. Exemptions exist for preparations containing no more than 2 mg per dosage unit or solutions with concentrations up to 0.25% totaling under 250 mg per package.
Available exclusively through medical prescription. Subject to controlled substance regulations governing benzodiazepine medications.
Controlled drug under the Misuse of Drugs Act 1975. Requires prescription for lawful possession and is subject to restrictions on manufacturing and distribution.
Listed as a controlled substance in Schedule III since April 2013. Subject to strict prescription requirements and regulatory oversight.
Requires the special green prescription form reserved for controlled medications. Possession or sale without valid prescription documentation is prohibited.
Controlled under the Controlled Substances Act as a Schedule IV depressant. Possession without a valid prescription or sale without proper licensing is prohibited. Available as a generic medication since 1997 and remains one of the most frequently prescribed benzodiazepines.
Classified as a controlled medication requiring special prescription protocols. The black stripe designation indicates heightened regulatory control due to dependence potential.
Controlled under Government Regulation 463/2013. Dispensed by prescription without requiring the blue stripe designation used for more strictly controlled substances.
Prescription-only medication under the Drugs and Cosmetics Rules. Sale without a valid prescription from a registered medical practitioner is prohibited.
Controlled under the Opium Act. Available only by prescription for medical use. Preparation, distribution, and transport without authorization are prohibited, though possession of small quantities for personal use is typically not prosecuted.
Designated as a narcotic substance in prescription category IV. Possession without a valid prescription constitutes an offense under Norwegian drug legislation.
Listed in Schedule B of controlled substances under Swiss narcotics legislation. Medicinal use is permitted with appropriate prescription.
Controlled under the Misuse of Drugs Act 1971. Unauthorized possession and supply are criminal offenses, though Class C substances carry less severe penalties than Class A or B drugs.
13 sources cited
